Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a chatbot keep dialysis patients on track between sessions?

NCT ID NCT07830810

NEW Symptom relief Sponsor: University of Rome Tor Vergata Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

People on hemodialysis must closely manage fluid, diet, and their vascular access between sessions, and sticking to these routines is hard. Researchers at the University of Rome Tor Vergata built DialysisBot, an AI chatbot that answers patient questions using only a hospital-approved knowledge base, and refuses to answer when it is unsure. The pilot study enrolls 20 to 40 adults on chronic hemodialysis who use the app for three months. Researchers measure how feasible and usable the chatbot is, whether it supports adherence, and how it affects quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DialysisBot, an AI chatbot that gives dialysis patients personalized self-management advice
What this could lead to
If it works, this could give dialysis patients a round-the-clock, hospital-approved helper for diet, fluid, and access questions, and shape larger trials of AI self-care tools.
What could go wrong
This is a small pilot of 20 to 40 patients at one center, so it cannot prove the chatbot improves health outcomes. Patients may not use it, may find it unhelpful, or may get answers that do not fit their situation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Patients undergoing chronic hemodialysis treatment * Availability of a compatible digital device (smartphone, tablet, or computer) * Adequate understanding of the Italian language * Sufficient basic digital literacy * Signed informed consent A purposive subsample (n = 10-15) of enrolled participants will additionally take part in semi-structured qualitative interviews at the end of the study. Exclusion Criteria: * Age under 18 years * Significant cognitive impairment preventing use of the application * Significant inability to use digital tools * Absence of signed informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chatbot-based training are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome congenital arteriovenous fistula Empowerment end stage renal failure Patient Participation Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chatbot-based training Hemodialysis Self-management

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centro Dialisi Molfetta

    Molfetta, Bari, 70056, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.